SavedAdd your journal

Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2026 / Cilt: 8 Sayı: 33

PRE-ECLAMPSIA: A GUIDE FOR MANAGEMENT TO PREVENT MATERNAL MORTALITY

PREEKLAMPSİA : ANNE ÖLÜMLERİNİN ÖNLENMESİNE YÖNELİK BİR YÖNERGE

Elif Gül Yapar Eyi(Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Ankara -TÜRKİYE)
Pages
1369–1379
Publication Date
2012-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The management of preeclampsia and the current strategies to prevent maternal deaths due to pre-eclampsia are presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pre-eclampsia is among the leading causes of maternal death in our country.
📊
Key Findings & Data:Pre-eclampsia is among the leading causes of maternal death in our country.
💡
Conclusion & Impact:The management of preeclampsia and the current strategies to prevent maternal deaths due to pre-eclampsia are presented.
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Pre-eklampsia · anne ölümü · eklampsia

Abstract

Pre-eclampsia is among the leading causes of maternal death in our country. The management of preeclampsia and the current strategies to prevent maternal deaths due to pre-eclampsia are presented.

Özet

Preeklampsia, ülkemizde anne ölümlerinin başta gelen nedenlerinden biridir. Preeklampsia yönetimi ve anne ölümlerinin önlenmesine yönelik stratejiler sunulmaktadır.

🔖

Cite This Article

Eyi, E. G. Y. (2012). PRE-ECLAMPSIA: A GUIDE FOR MANAGEMENT TO PREVENT MATERNAL MORTALITY. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 8 Sayı: 33, 1369–1379. https://ajindex.com/articles/1420543

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (40)

  1. Duley L: The global impact of pre-eclampsia and eclampsia: Semin Perinatol 2009, 33 (3); 130-7
  2. Redman CWG, Jacobson Sl, Russell R: Hypertension in pregnancy in de Swiet’s Medical Disorders in Obstetric Practice (Raymond O Powrie, Michael F Greee, William Camannn eds) page 153-81, Fifth edition, 2010. McMillan Company, Singapore
  3. Barış E, Mollahaliloğlu S, Aydın S: Healthcare in Turkey: from laggard to leader: BMJ 2011, 342, c 7456 doi 10.1136/bmj c 7456
  4. WHO and UNICEF estimation of maternal mortality for 2000 and 2003 and 2010 maternal mortality projected by Turkish Ministry of Health
  5. WHO Statistics, 2010
  6. Centre for Maternal and Child Enquiries(CMACE): Saving Mother’s Lifes: reviewing maternal deaths to make motherhood safer:2006-08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118(Suppl. 1) 1:203
  7. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM The classification and diagnosis of hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy(ISSHP). Hypertens Foundation, 2011: (Charity No: 1037116).
  8. National Collaborating Centre for Women’s and Children’s Health. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. National Institute for Health and Clinical Excellence Guideline 107. London: RCOG. August 2010. [www. guidance. nice.org.uk/CG107/]. Accessed 5 October 2010.
  9. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-1890
  10. The Eclampsia Trial Collaborative Group: Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345:1455-63
  11. Baxter JK, Weinstein L: HELLP syndrome: the state of the art. Obstet Gynecol Surv 2004, 59:838-845.
  12. Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008;57:951–6
  13. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011 Jan;31(1):66-74. doi: 10.1002/pd.2660
  14. Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH:. Maternal serum placental growth factor (PlGF) at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Ultrasound Obstet Gynecol 2008 32:732–739.
  15. Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11 to 13 weeks of gestation in hypertensivedisorders of pregnancy. Prenat Diagn 2009a 29: 75 3–760.
  16. Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH. Maternal serum activin A at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009b.25: 322–327.
  17. Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaides KH. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn2009c. 29: 934–938.
  18. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009d 29: 1103–1108.
  19. Akolekar R, Veduta A, Minekawa R, Chelemen T, Nicolaides KH.Maternal plasma P-selectin at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Hypertens Pregnancy 2010 DOI: 10.3109/106419509032 42683.
  20. Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension 2009: 53: 747–748.
  21. Foidart JM, Manuat C, Akolekar R, Cruz J, Nicolaides KH. Maternal plasma soluble endoglin at 11–13 weeks of pregnancy in preeclampsia. Ultrasound Obstet Gynecol 35: 680–687.
  22. Giguere Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a system atic review.Clin Chem 2010 56: 361–374.
  23. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2007; 30: 742–749.
  24. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010a 24: 104–110.
  25. Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11–13 weeks. Hypertens Pregnancy 2010b DOI: 10.3109 / 10641955.2010.484086
  26. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a metaanalysis Obstet Gynecol 2010 116: 402–414.
  27. Şen C: Management of Severe Pre-eclampsia and Eclampsia (Chapter 202) in Textbook of Perinatal Medicine(Asım Kurjak, Frank A Chervenak eds), pp 2688-97, Second Edition, Informa Healthcare, 2006, UK
  28. McDonald SJ, Abbott JN, Higgins SP. Prophylactic ergometrineoxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004;Issue 1:CD000201
  29. Frederick U. Eruo and Baha M. Sibai: Hypertensive diseases in pregnancy in Clinical Obstetrics(E.Albert Reece, John C Hobbins eds) Clinical Obstetrics: The Fetus and Mother Blackwell Publishing Third Edition, Hong Kok, 683-99, 2007
  30. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994;309:1395–400.
  31. Knight M. Eclampsia in the United Kingdom 2005. BJOG 2007;114:1072–8.
  32. Sibai BM: Hypertensive Emergencies(chapter 5) in Obstetric Intensive Care Manual (Michael Foley, Thomas R Strong, Thomas J Garite eds), pp 49-60, McGraw Hill, New York 2011
  33. Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11 to 13 weeks of gestation in hypertensivedisorders of pregnancy. Prenat Diagn 2009a 29: 75 3–760.
  34. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009d 29: 1103–1108.
  35. Akolekar R, Veduta A, Minekawa R, Chelemen T, Nicolaides KH.Maternal plasma P-selectin at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Hypertens Pregnancy 2010 DOI: 10.3109/106419509032 42683.
  36. Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension 2009: 53: 747–748.
  37. Foidart JM, Manuat C, Akolekar R, Cruz J, Nicolaides KH. Maternal plasma soluble endoglin at 11–13 weeks of pregnancy in preeclampsia. Ultrasound Obstet Gynecol 35: 680–687.
  38. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2007; 30: 742–749.
  39. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010a 24: 104–110.
  40. Frederick U. Eruo and Baha M. Sibai: Hypertensive diseases in pregnancy in Clinical Obstetrics(E.Albert Reece, John C Hobbins eds) Clinical Obstetrics: The Fetus and Mother Blackwell Publishing Third Edition, Hong Kok, 683-99, 2007